Malt-O-Meal is recalling their unsweetened puffed rice and unsweetened puffed wheat cereals. The company says those products could be contaminated with salmonella.
The voluntary recall affects cereals produced with "best if used by" codes between April 8, 2008, and March 18, 2009. The cereals are distributed nationally both under the malt-o-meal brand and some private label brands.
No illnesses have been reported, but if you have purchased any of these cereals you can return them for a full refund.
For more information about the recall including photos of affected products, you can call Malt-O-Meal Consumer Affairs at 1-877-665-9331.
Information regarding this recall, including images of the Malt-O-Meal product packaging also will be posted to the company's website at:
Taken as a pill once a day, it could make treatment for millions easier, more effective
Small, early study used electrical nerve stimulation and tone therapy for hard-to-treat tinnitus
Following a healthy diet runs about $1.50 more a day than junk food, study finds
'Insulin sensitizers' tied to lower odds of developing cancer when compared to other type of medication
What Happens If My Income Changes After I Receive An Insurance Subsidy?
In one of the biggest advances against leukemia and other blood cancers in many years, doctors are reporting unprecedented success by using gene therapy to transform patients' blood cells into soldiers that seek and destroy cancer.
By Tova Cohen TEL AVIV (Reuters) - Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018. This figure could jump to $3 billion in 2020, Elisabeth Kogan, Teva's senior vice president of generic research and development, told reporters on Sunday. The NTE program, launched a year ago, is a major element in Teva's strategy for growth and the company has 15 such products in its pipeline. One such product, called Adasuve, which it licensed from Alexza Pharmaceuticals, has been approved and is expected to be launched in the United States in about a month, Teva officials said.